A compound of formula (I) wherein R is a radical selected from in which R.sub.7 is halogen, cyano, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl or trifluoromethoxy; p is an integer from 0 to 3; R.sub.1 is hydrogen, halogen, cyano, C.sub.2-4 alkenyl, C.sub.1-4 alkyl optionally substituted by halogen, cyano or C.sub.1-4 alkoxy; R.sub.2 is hydrogen or C.sub.1-4 alkyl; R.sub.3 and R.sub.4 independently are hydrogen, C.sub.1-4 alkyl or R.sub.3 together with R.sub.4 is C.sub.3-7 cycloalkyl; R.sub.5 is phenyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C.sub.1-4 alkyl, cyano, C.sub.1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC.sub.1-4 alkyl, naphthyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C.sub.1-4 alkyl, cyano, C.sub.1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC.sub.1-4 alkyl, a 9 to 10 membered fused bicyclic heterocyclic group substituted by 1 to 3 groups independently selected from trifluoromethyl, C.sub.1-4 alkyl, cyano, C.sub.1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC.sub.1-4 alkyl or R.sub.5 is a 5 or 6 membered heteroaryl group substituted by 1 to 3 groups independently selected from trifluoromethyl, C.sub.1-4 alkyl, cyano, C.sub.1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC.sub.1-4 alkyl; R.sub.6 is hydrogen or (CH.sub.2)qR.sub.8; R.sub.8 is hydrogen, C.sub.3-7 cycloalkyl, C.sub.1-4 alkoxy, amine, C.sub.1-4 alkylamine, (C.sub.1-4 alkyl).sub.2amine, OC(O)NR.sub.9R.sub.10 or C(O)NR.sub.9R.sub.10; R.sub.9 and R.sub.10 independently are hydrogen, C.sub.1-4 alkyl or C.sub.3-7 cycloalkyl; m is zero or 1; n is 1 or 2; q is an integer from 1 to 4; r is 1 or 2; or pharmaceutically acceptable salts and solvates thereof; processes for their preparation to pharmaceutical compositions containing them and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.